Atomo Diagnostics Ltd (ASX: AT1) Share Price and News
Price
$0.019
Movement
0.00 (0.0)
as at 15 Aug - Closed (20 mins delayed)
52 Week Range
$0.014 - $0.025
1 Year Return
-20.83%
Atomo Diagnostics Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$14.97 million
P/E Ratio
N/A
Dividend Yield
0.00%
Shares Outstanding
787.66 million
Earnings per share
-0.010
Dividend per share
N/A
Year To Date Return
N/A
Earnings Yield
N/A
Franking
-
Share Price
$0.019
Day Change
0.00 (0.0)
52 Week Range
$0.014 - $0.025
Yesterday's Close
$0.019
Today's Open
$0.019
Days Range
$0.018 - $0.019
Volume
4,226,083
Avg. Volume (1 month)
2,506,933
Turnover
$76,941
as at 15 Aug - Closed
Atomo Diagnostics Ltd (ASX: AT1)
Latest News
Healthcare Shares
Why is the Atomo Diagnostics (ASX:AT1) share price halted?
Share Gainers
These were the 5 top performing ASX shares in September
Share Market News
Why the Atomo Diagnostics (ASX:AT1) share price has rallied 15% today
Share Gainers
Why the Atomo Diagnostics (ASX:AT1) share price has soared 30% in a week
Earnings Results
Atomo Diagnostics (ASX:AT1) share price sinks 8% on FY21 results
Share Gainers
Here's why the Atomo (ASX: AT1) share price flew 4% higher today
Share Market News
The Atomo (ASX:AT1) share price has shot up 9%. Here's why
Healthcare Shares
Ellume is making news and these ASX shares are surging, again
Healthcare Shares
Here's why the Atomo (ASX:AT1) share price is soaring 10%
Share Gainers
Why Atomo, Metcash, Temple & Webster, & Woolworths are pushing higher
Share Market News
Atomo Diagnostics (ASX:AT1) share price rockets 59% on COVID-19 test update
Healthcare Shares
The Atomo (ASX:AT1) share price is soaring today. Here's why
AT1 ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| 15th Aug 2025 2025-08-15T11:43:49 | Notification regarding unquoted securities - AT1 | YesNo | 11:43am | 7 | 19k |
| 15th Aug 2025 2025-08-15T11:37:34 | Application for quotation of securities - AT1 | YesNo | 11:37am | 6 | 16k |
| 13th Aug 2025 2025-08-13T09:43:33 | Successful Placement from Share Purchase Plan Shortfall | YesNo | 9:43am | 2 | 210k |
| 7th Aug 2025 2025-08-07T09:34:20 | Atomo secures order for Pascal worth US$410,000 from Lumos | YesNo | 9:34am | 2 | 219k |
| 29th Jul 2025 2025-07-29T09:49:03 | Quarterly Activities/Appendix 4C Cash Flow Report | YesNo | 9:49am | 12 | 1.6M |
| 25th Jul 2025 2025-07-25T16:48:01 | Atomo Investor Webinar Presentation | YesNo | 4:48pm | 1 | 180k |
| 24th Jul 2025 2025-07-24T18:52:44 | Change in substantial holding | YesNo | 6:52pm | 3 | 390k |
| 24th Jul 2025 2025-07-24T11:26:42 | Notification regarding unquoted securities - AT1 | YesNo | 11:26am | 7 | 19k |
| 24th Jul 2025 2025-07-24T11:08:52 | Application for quotation of securities - AT1 | YesNo | 11:08am | 6 | 16k |
| 21st Jul 2025 2025-07-21T10:21:31 | Successful Placement from Share Purchase Plan Shortfall | YesNo | 10:21am | 2 | 188k |
About Atomo Diagnostics Ltd
Atomo Diagnostics Limited is a medical device company. Its Rapid Diagnostic Test devices are used both by healthcare professionals and by consumers to screen for a range of diseases and medical conditions
AT1 Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 15 Aug 2025 | $0.02 | $0.00 | 0.00% | 4,226,083 | $0.02 | $0.02 | $0.02 |
| 14 Aug 2025 | $0.02 | $0.00 | 0.00% | 138,220 | $0.02 | $0.02 | $0.02 |
| 13 Aug 2025 | $0.02 | $0.00 | 0.00% | 744,800 | $0.02 | $0.02 | $0.02 |
| 12 Aug 2025 | $0.02 | $0.00 | 0.00% | 2,341,183 | $0.02 | $0.02 | $0.02 |
| 11 Aug 2025 | $0.02 | $0.00 | 0.00% | 1,091,416 | $0.02 | $0.02 | $0.02 |
| 08 Aug 2025 | $0.02 | $0.00 | 0.00% | 848,689 | $0.02 | $0.02 | $0.02 |
| 07 Aug 2025 | $0.02 | $0.00 | 0.00% | 6,649,426 | $0.02 | $0.02 | $0.02 |
| 06 Aug 2025 | $0.02 | $0.00 | 0.00% | 2,306,925 | $0.02 | $0.02 | $0.02 |
| 05 Aug 2025 | $0.02 | $0.00 | 0.00% | 5,188,961 | $0.02 | $0.02 | $0.02 |
| 04 Aug 2025 | $0.02 | $0.00 | 0.00% | 567,251 | $0.02 | $0.02 | $0.02 |
| 01 Aug 2025 | $0.02 | $0.00 | 0.00% | 5,051,847 | $0.02 | $0.02 | $0.02 |
| 31 Jul 2025 | $0.02 | $0.00 | 0.00% | 314,621 | $0.02 | $0.02 | $0.02 |
| 30 Jul 2025 | $0.02 | $0.00 | 0.00% | 121,371 | $0.02 | $0.02 | $0.02 |
| 29 Jul 2025 | $0.02 | $0.00 | 0.00% | 35,339 | $0.02 | $0.02 | $0.02 |
| 28 Jul 2025 | $0.02 | $0.00 | 0.00% | 1,843,568 | $0.02 | $0.02 | $0.02 |
| 25 Jul 2025 | $0.02 | $0.00 | 0.00% | 2,534,764 | $0.02 | $0.02 | $0.02 |
| 24 Jul 2025 | $0.02 | $0.00 | 0.00% | 471,612 | $0.02 | $0.02 | $0.02 |
| 23 Jul 2025 | $0.02 | $0.00 | 0.00% | 994,962 | $0.02 | $0.02 | $0.02 |
| 22 Jul 2025 | $0.02 | $0.00 | 0.00% | 203,983 | $0.02 | $0.02 | $0.02 |
| 21 Jul 2025 | $0.02 | $0.00 | 0.00% | 63,418 | $0.02 | $0.02 | $0.02 |
| 18 Jul 2025 | $0.02 | $0.00 | 0.00% | 1,707,933 | $0.02 | $0.02 | $0.02 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 27 Jun 2025 | John Kelly | Issued | 1,621,622 | $30,000 |
Issue of securities.
|
| 27 Jun 2025 | John Kelly | Issued | 1,621,622 | $24,324 |
Issue of securities.
|
| 27 Jun 2025 | Anthony May | Issued | 540,541 | $10,000 |
Issue of securities.
|
| 27 Jun 2025 | Anthony May | Issued | 540,541 | $8,108 |
Issue of securities.
|
| 27 Jun 2025 | Patrick Cook | Issued | 540,541 | $10,000 |
Issue of securities.
|
| 27 Jun 2025 | Patrick Cook | Issued | 540,541 | $8,108 |
Issue of securities.
|
| 14 Apr 2025 | John Kelly | Expiry | 666,666 | $14,666 |
Options expired.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Mr John Michael Kelly | FounderChief Executive OfficerManaging Director | Apr 2010 |
Mr Kelly has focused on developing and commercializing innovative healthcare products that enhance usability and performance, having started with CR Bard in Europe developing Class III implantable cardiology products. Prior to joining Unilife in 2005, Mr Kelly spent five years at ResMed where he led the New Product Implementation Group and managed the development of the Mirage Swift and Activa mask systems.
|
| Dr Cheri Louise Walker | Non-Executive Director | Nov 2022 |
Dr Walker is an executive with more than twenty-five years of experience working with life science and diagnostic companies. Dr. Walker is currently the President, Chief Executive Officer, and Director of Rhinostics. She has previously held senior executive positions at Abcam; Charles River Labs; Qiagen, and Life Technologies, now part of ThermoFisher. He is a member of the Risk Committee.
|
| Mr Anthony May | Non-Executive Director | May 2025 |
Mr May has held various Director roles across international corporations including Hoechst Germany, Microgenics Corporation USA, Fisher Scientific and Thermo Fisher Scientific. With experience across public and private pathology laboratories, as well as sales and management roles in the IVD supply sector, he has built a record in business leadership and strategic growth.
|
| Mr Patrick Cook | Non-Executive Director | May 2025 |
Mr Cook is a Non-Executive Director and Chair with over 20 years of board level experience and over 30 years experience in senior executive positions in medical devices & point-of-care diagnostics sectors within multinational and listed biotechnology companies Mr Cook currently serves as Non-Executive Director & previously Chair, at Workplace Drug Testing Australasia Ltd and as Committee Member & previously Member of the Executive at Animal Ethics Committee QUT. He previously served as Non-Executive Director & Chair at eWaste Connection Ltd, Board Member at Prostate Cancer Foundation of Australia (Qld).
|
| Mr Mathew Leslie Watkins | Company Secretary | Jun 2024 |
-
|
| Mathew Leslie Watkins | Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| GZ Family Holdings Pty Ltd | 79,787,536 | 12.48% |
| Dalraida Holdings Pty Limited | 65,120,000 | 10.19% |
| Global Health Investment Fund | 64,811,280 | 10.14% |
| Mr Xiaoyi Lin | 11,880,000 | 1.86% |
| Grand Challenges Canada | 11,390,824 | 1.78% |
| Liverbird Pty Ltd | 10,931,653 | 1.71% |
| Australia West Holdings Pty | 10,500,000 | 1.64% |
| Australia North Holdings Pty | 9,580,000 | 1.50% |
| ID&E Pty Ltd | 9,032,248 | 1.41% |
| Mark Andrew Smith | 7,790,224 | 1.22% |
| Mr Ian Fredrick Johnson | 7,506,080 | 1.17% |
| John Michael Kelly | 7,370,248 | 1.15% |
| Leo James Lynch | 7,321,121 | 1.15% |
| Citicorp Nominees Pty Limited | 6,355,684 | 0.99% |
| Mr Ankur Choudhary | 5,887,126 | 0.92% |
| Ruth Karen Devney | 5,626,408 | 0.88% |
| Sokolov Pty Ltd | 4,031,888 | 0.63% |
| H & L Management Pty Ltd | 4,000,000 | 0.63% |
| Rue Des Rocs Pty Ltd | 3,800,000 | 0.59% |
| Miss Lisa Marie Mackenzie | 3,351,968 | 0.52% |